{"id":967,"date":"2023-04-06T16:51:49","date_gmt":"2023-04-06T16:51:49","guid":{"rendered":"http:\/\/new.patterncomputer.com\/?p=967"},"modified":"2023-04-11T20:28:59","modified_gmt":"2023-04-11T20:28:59","slug":"pattern-and-cellus-group-team-up-to-test-disruptive-new-diagnostic-instrument","status":"publish","type":"post","link":"http:\/\/new.patterncomputer.com\/pattern-and-cellus-group-team-up-to-test-disruptive-new-diagnostic-instrument\/","title":{"rendered":"Pattern and Cellus Group team up to test disruptive new diagnostic instrument"},"content":{"rendered":"
Pattern Discovery Engines\u2122 accurately detect increasing number of diseases in 3 seconds using 2 drops of saliva<\/strong><\/p>\n REDMOND, WA, APRIL 6, 2023<\/strong> — Pattern Computer\u00ae, Inc. (Pattern) is pleased to announce that Cellus Group and Pattern are collaborating to test Pattern’s innovative, portable AI\/ML device to accurately detect key respiratory diseases in 3 seconds using 2 drops of saliva (including Covid-19, RSV, Influenza, Rhinovirus, and others.)<\/p>\n Pattern has developed a novel diagnostic research instrument, ProSpectral\u2122, that dramatically improves the speed and availability of testing respiratory diseases with the same accuracy as PCR tests.<\/p>\n ProSpectral offers a unique combination of improvements over existing test systems: Cellus Group in 2022 completed studies to support initial validation of ProSpectral’s data modelling. It will now begin further studies and gather 2,000 fresh samples, scan them with ProSpectral, and test them for viral cross-specificity. This will contribute to finalizing ProSpectral’s initial disease modelling and eventual design of clinical trials.<\/p>\n The technology ProSpectral uses is fundamentally different from current relevant technologies for respiratory disease detection. Pattern’s solution leverages advanced spectrophotometry combined with highly advanced AI\/ML analytics.<\/p>\n ProSpectral allows for vastly faster diagnosis, boosting patient throughput and satisfaction. It enables fast, easy point-of-entry screening of staff\/patients\/visitors at hospitals, clinics, schools, businesses, transportation to protect operational capability. It is also ideal for mobile testing at indoor or outdoor locations with little infrastructure.<\/p>\n About Cellus Group,<\/strong> a Chilean biotechnology multinational with a site in Le\u00f3n-Spain,<\/p>\n Collaborating in the development of ProSpectral in one of the Cellus Groups’ important initiatives as a leader in supporting and bringing to market innovations in biotechnology. Cellus plans to offer ProSpectral’s unique capabilities and efficiencies to hospital and clinic clients across Latin America, Spain, and beyond.<\/p>\n Cellus Contacts:
\n\u2022 3-second time-to-results (TTR) enables vastly faster diagnosis, boosting patient throughput and satisfaction
\n\u2022 Exceptional balanced accuracy of 98.5% matches that of PCR tests
\n\u2022 NO reagents are required \u2013 no toxic waste for facility to handle and dispose of
\n\u2022 Only 2 drops of saliva required \u2013 no invasive, unpleasant nasopharyngeal swabs
\n\u2022 Small and portable (shoe box-sized and < 8lbs) – perfect for mobile testing
\n\u2022 Can process 1200 samples per hour
\n\u2022 Very simple operation, training, and maintenance – no medical licensure required
\n\u2022 Detecting new diseases and variants only requires a remote software update
\n\u2022 Much less expensive than other tests requiring reagents and complex equipment<\/p>\n
\nFrancisco Aulestia, CTO, CELLUS GROUP francisco.aulestia@cellus.cl<\/a>
\nRodrigo Arancibia, CEO \/ Founder CELLUS GROUP, rodrigo.arancibia@cellus.cl<\/a><\/p>\n